Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
S-1/Leucovorin (SL) Versus sLV5FU2 as the First-line Treatment for Elderly Patients With Colorectal Cancer
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2010-09-02
- Last Posted Date
- 2010-09-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT01193452
- Locations
- 🇨🇳
Jin Li', Shanghai, Shanghai, China
Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients
Phase 2
- Conditions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2010-09-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT01192230
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
Phase 2
- Conditions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2010-09-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 68
- Registration Number
- NCT01192243
- Locations
- 🇨🇳
Cancer hospital Fudan University, Shanghai, Shanghai, China
Gemcitabine,Vincristine and Cisplatin as Second Line Combination Therapy in Patients With Sarcoma
Phase 2
- Conditions
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2010-09-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT01192633
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Study of Apatinib in Metastatic Triple-Negative Breast Cancer Patients
- First Posted Date
- 2010-08-06
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT01176669
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Efficacy and Safety Study of Trastuzumab, Paclitaxel and Carboplatin on HER2+ Preoperative Breast Cancer
- First Posted Date
- 2010-07-27
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 60
- Registration Number
- NCT01170143
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-06-24
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 73
- Registration Number
- NCT01149798
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, China
Minimally Invasive Esophagectomy (MIE) in Prone Versus Left Decubitus Position
Phase 2
- Conditions
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2011-03-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 2
- Registration Number
- NCT01144325
- Locations
- 🇨🇳
Zhong Shan Hospital, Fu Dan University, Shanghai, China
Study of Urinary Angiotensinogen as a Marker to Warn the Deterioration of Renal Function in CKD Patients Early.
- First Posted Date
- 2010-05-06
- Last Posted Date
- 2010-05-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 400
- Registration Number
- NCT01118494
- Locations
- 🇨🇳
Nephrology Department of Huashan Hospital, Shanghai, Shanghai, China
Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy
Phase 4
- Conditions
- Interventions
- First Posted Date
- 2010-04-13
- Last Posted Date
- 2010-04-13
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 80
- Registration Number
- NCT01102335
- Locations
- 🇨🇳
Liver cancer institute, Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath